Cockroach Allergy Shots: Why Integrated Pest Management Comes Before SCIT
Cockroach sensitization is the single strongest predictor of asthma morbidity in inner-city US children (Rosenstreich 1997 NEJM, 1,528 children), yet the CRITICAL trial (Wood 2022 JACI) — the definitive randomized controlled trial of cockroach SCIT in 57 children — found that nasal allergen challenge responses did NOT differ between cockroach SCIT and placebo (P=0.63).
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Cockroachis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Cockroach Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to cockroach — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of cockroach allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of cockroach immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of cockroach extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for cockroach allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing cockroach extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription cockroach immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat cockroach allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Cockroach?
The biology, taxonomy, and clinical fingerprint of Cockroach — the foundation of how SCIT targets it.
Cockroach allergens (Bla g 1, Bla g 2, Bla g 5) in fecal particles and body fragments accumulate in bedrooms, kitchens, and upholstered furniture of infested dwellings — persistently present even after extermination without professional IPM.
- Scientific name
- Blattella germanica (German cockroach) + Periplaneta americana (American cockroach)
- Family
- Blattidae / Ectobiidae (Blattodea)Cockroach order
- Type
- Indoor perennial allergen — fecal particles, cast skins, saliva, body parts
- Native to
- Tropical Asia (B. germanica); Africa/Middle East (P. americana); now cosmopolitan in human-inhabited buildings worldwide
- Allergen proteins
- Bla g 1 (microvilli-like protein, 46 kDa, 30–58% IgE reactivity)Bla g 2 (inactive aspartic protease, 36 kDa, ~57.6% reactivity, species-specific B. germanica)Bla g 4 (lipocalin, 21 kDa, ~41%, male-specific)Bla g 5 (glutathione S-transferase, 23 kDa, up to 70% in US cohorts)Bla g 7 (tropomyosin, 33 kDa, 10–42%) — pan-allergen, ~80% identity to Der p 10 and shrimp Pen a 1Per a 1, Per a 2, Per a 7 (P. americana allergens)Per a 9 (arginine kinase, 80% reactivity in rhinitis)
- Particle size
- Fecal particles 10–30 µm; cockroach body fragments can be smaller and more airborne
- Avoidance difficulty
- Very difficult
How Cockroach Allergy Presents
Symptoms by body system — useful for distinguishing Cockroach sensitivity from overlapping allergies and infections.
Respiratory
- Perennial rhinitis from year-round indoor cockroach allergen exposure
- Asthma exacerbations — cockroach sensitization + high exposure is the strongest single predictor of asthma morbidity in inner-city children (Rosenstreich 1997 NEJM)
- Chronic cough and wheezing in infested households
- Asthma hospitalizations and emergency visits correlated with cockroach allergen load (Morgan 2004 NEJM)
Ocular
- Allergic conjunctivitis from airborne cockroach particle exposure
- Perennial eye itching and redness in infested homes
- Tearing and periorbital puffiness in heavily sensitized patients in high-exposure environments
Dermal
- Atopic dermatitis flares in cockroach-sensitized children with high home exposure
- Urticaria in rare contact hypersensitivity cases
- Eczema exacerbations correlating with seasonal cockroach population peaks
Systemic
- Severe asthma requiring ER visits and hospitalizations — 2.1 fewer unscheduled visits/year with comprehensive environmental intervention (Morgan 2004 NEJM ICAS)
- 4.4 fewer missed school days/year with IPM-inclusive environmental intervention
- Missed work days and healthcare costs disproportionately affecting low-income urban families in heavily infested housing
The CRITICAL trial is the most important negative trial in urban pediatric allergy of the past decade. It doesn't mean cockroach SCIT can never work — it means the current non-standardized extracts with 728-fold variability in Bla g 2 content cannot deliver reliable efficacy. The field needs standardized recombinant extracts before SCIT can be recommended. Until then, IPM with professional extermination and housing remediation delivers the bulk of the clinical benefit.
Where Cockroach Triggers Year-Round
Cockroach is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundPerennial allergen — cockroach populations peak in warm summer months but allergen persists year-round in infested buildings· Year-round exposure in infested dwellings; allergen accumulates in mattresses, kitchen cabinets, and upholstered furniture
US Exposure Map
15 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Moderate
- NY:
- High
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- High
- IN:
- Moderate
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- Low
- RI:
- Low
- CA:
- Moderate
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Moderate
- KY:
- Moderate
- WV:
- Moderate
- VA:
- High
- MD:
- High
- DE:
- Low
- AZ:
- Moderate
- NM:
- Moderate
- KS:
- Low
- AR:
- Moderate
- TN:
- Moderate
- NC:
- Moderate
- SC:
- Moderate
- OK:
- High
- LA:
- High
- MS:
- High
- AL:
- High
- GA:
- High
- TX:
- High
- FL:
- High
- AK:
- Low
- HI:
- Low
What Cockroach Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Bla g 7 (tropomyosin) creates medically significant cross-reactivity between cockroach and dust mite allergens, and between cockroach and shrimp — a clinically important food allergen connection in cockroach-sensitized patients.
Bla g 7 / Der p 10 tropomyosin ~80% identity — documented cross-reactivity
Pen a 1 shrimp tropomyosin ~80% identity to Bla g 7 — confirmed food cross-reactivity; cockroach-sensitized patients may react to shrimp
Tropomyosin pan-allergen — cockroach + dual-Dermatophagoides combined sensitization is common in inner-city pediatric asthma
Shellfish tropomyosin cross-reactivity via Bla g 7 homology
Cockroach-Shellfish Tropomyosin Syndrome
Bla g 7 (cockroach tropomyosin) shares ~80% amino acid identity with shrimp Pen a 1 tropomyosin. Cockroach-sensitized patients — particularly in urban populations — may experience allergic reactions to shrimp, lobster, crab, and other shellfish via this tropomyosin cross-reactivity. This is not oral allergy syndrome in the traditional pollen-food sense, but true IgE cross-reactivity via a shared pan-allergen.
Is SCIT Right for Your Cockroach Allergy?
Answer 5 questions to assess your cockroach allergy burden and whether IPM, pharmacotherapy, or evaluation for experimental SCIT is the appropriate next step.
What type of housing or workplace exposure do you have to cockroaches?
The Cockroach SCIT Protocol
Cockroach SCIT remains experimental following the negative CRITICAL trial. When pursued despite this evidence gap (for severe persistent disease after IPM failure and pharmacotherapy optimization), standard non-standardized build-up applies with explicit informed consent about uncertain efficacy.
Integrated Pest Management is the first-line Level A evidence intervention: professional extermination with gel bait stations (avoid chemical sprays that worsen asthma), sealing cracks and entry points, removing food and water sources, cleaning mattresses and encasing in allergen-barrier covers, removing clutter where cockroaches nest. A single NYC public housing IPM visit was more effective than regular pesticide application (Environ Health Perspect 2009).
If experimental cockroach SCIT is pursued after IPM failure and informed consent, standard non-standardized build-up protocol applies. No reliable Bla g 1 or Bla g 2 dosing benchmarks exist due to 728-fold variability in commercial extract Bla g 2 content. Extract selection and dosing must be guided by a specialist experienced in non-standardized allergen compounding.
Maintenance injections continue with concurrent IPM reinforcement. Annual reassessment of cockroach allergen levels (dust sampling for Bla g 1 and Bla g 2) and symptom burden guides continuation decisions.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Cockroach SCIT
Cockroach SCIT efficacy is not established. The definitive randomized controlled trial (CRITICAL, 2022) found no significant benefit. IPM-based environmental intervention, in contrast, has documented clinical benefit from the ICAS trial (Morgan 2004 NEJM).
- Cockroach SCIT vs placebo: nasal challenge response (CRITICAL trial 2022)0%Wood RA et al., J Allergy Clin Immunol Pract 2022 — 57 children, 12 months cockroach SCIT; nasal challenge P=0.63 (no significant difference from placebo)
- Comprehensive environmental intervention (IPM-inclusive): symptom-days reduction (Morgan 2004 NEJM)60%Morgan WJ et al., NEJM 2004;351:1068 — 937 children, 7 US cities; 21.3 fewer symptom days/year (19.5% reduction) vs usual care
- Cockroach SCIT: immunologic effect (IgG4 elevation, T-cell modulation, CRITICAL trial)30%Wood RA et al., JACI Pract 2022 — immunologic effects documented despite negative clinical endpoint; supports mechanism but not clinical utility with current non-standardized extracts
Cockroach SCIT induces immunologic changes but failed to demonstrate clinical benefit in the CRITICAL trial (P=0.63 on nasal challenge). The likely cause is 728-fold variability in Bla g 2 content across commercial extracts, preventing reliable dose delivery. IPM-based environmental intervention (Morgan 2004 NEJM: 21.3 fewer symptom days/year) has the strongest evidence for cockroach allergy management.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Cockroach SCIT Side Effects
Cockroach SCIT side effects are extrapolated from general arthropod allergen SCIT and non-standardized extract experience. Higher reaction rates are expected with non-standardized allergens compared to FDA-standardized extracts.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling and erythema | Rate 30–50% | Mild |
Injection-site itching | Rate 25–40% | Mild |
Large local reaction (>5 cm) Higher rate with non-standardized extracts due to inconsistent allergen content | Rate 10–20% | Moderate |
Delayed local reaction | Rate 10–15% | Mild |
Systemic reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis/asthma flare Asthma control must be verified before each injection — pre-injection peak flow >80% predicted | Rate 2–5% | Moderate |
Urticaria | Rate 0.5–1% | Moderate |
Systemic anaphylaxis All SCIT requires 30-minute clinic observation with epinephrine | Rate <0.2% | Severe |
All SCIT requires a 30-minute observation period with clinic-based epinephrine. Asthma must be well-controlled before each cockroach SCIT injection — uncontrolled asthma is a contraindication to injection. Given non-standardized extract variability, higher reaction rates are expected for cockroach compared to FDA-standardized allergens.
SCIT vs Alternatives for Cockroach
For cockroach allergy, Integrated Pest Management has Level A evidence and should precede any SCIT discussion. Curex at-home blood testing includes Bla g 1, Bla g 2, and Bla g 5 component testing — identifying the cockroach-sensitized subset of dust mite-allergic patients whose persistent symptoms may reflect dual sensitization that IPM alone may not address.
| Criterion | IPM (First-line)Best | At-Home Dust Mite SCIT (Curex, if co-sensitized) | Cockroach SCIT (experimental) | Pharmacotherapy |
|---|---|---|---|---|
| Effectiveness | Moderate–high (21.3 fewer symptom days/yr, ICAS) | High for D. farinae/pteronyssinus | Unproven (CRITICAL trial negative) | Controls symptoms |
| Cost | $200–$800 for professional IPM | $3,500–$8,000 | $3,500–$8,000 | $500–$2,500/yr |
| Duration | Ongoing | 3–5 years | 3–5 years | Indefinite |
| Convenience | Housing-based intervention | At-home self-injection; weekly build-up | Weekly clinic visits | Daily medication |
| Safety | Safest (avoid chemical sprays) | Virtual Shot Room–supervised dosing + prescribed epi | Non-std extract risks | Generally safe |
| Evidence level | Level A evidence | FDA-standardized, multiple RCTs | Experimental only | Standard of care |
IPM (First-line)Best
At-Home Dust Mite SCIT (Curex, if co-sensitized)
Cockroach SCIT (experimental)
Pharmacotherapy
IPM combined with optimized asthma pharmacotherapy is the evidence-based first-line approach for cockroach allergy. For patients who also have Dermatophagoides dust-mite sensitization — common given Bla g 7 / Der p 10 tropomyosin cross-reactivity — Curex delivers dust-mite immunotherapy as an at-home allergy shot with pricing confirmed in a current program quote: a serum compounded under USP <797>, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector confirmed on hand, and allergist-overseen escalation — targeting the allergen with the strongest evidence base.
What Cockroach SCIT Actually Costs
Coverage for cockroach SCIT may be limited given its experimental status and the absence of FDA-standardized extract. IPM costs are generally not covered as medical benefits but may be accessible through housing authority programs in HUD-funded housing. Patients should discuss SCIT coverage with their insurer before pursuing this experimental therapy.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your cockroach allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Cockroach SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
The CRITICAL trial (Wood et al. 2022 JACI Practical/JACI, 57 children ages 8–17) randomized cockroach-sensitized children to 12 months of cockroach SCIT versus placebo. Despite producing immunologic changes (IgG4 elevation, T-cell modulation confirming the shots were biologically active), nasal allergen challenge responses did not differ significantly between groups (P=0.63). This negative result most likely reflects extract quality problems — commercial cockroach extracts show up to 728-fold variability in Bla g 2 content — rather than a definitive proof that cockroach immunotherapy is biologically impossible. Standardized recombinant cockroach extracts may produce better results in future trials. For now, SCIT for cockroach is experimental.
Rosenstreich and colleagues (NEJM 1997, 1,528 children across 8 US metropolitan areas) found that cockroach sensitization combined with high bedroom allergen levels (>8 units/gram Bla g 1) was the single strongest predictor of asthma morbidity — more powerful than dust mite sensitization and cat sensitization at equivalent exposure levels. Three factors make cockroach uniquely dangerous: allergen is perennial (no seasonal remission), levels are highest in bedrooms (where children sleep and spend the most time), and the allergens are potent with Bla g 5 (glutathione S-transferase) reaching 70% IgE reactivity in US urban cohorts. The NCICAS showed 85.3% of inner-city bedrooms across 8 major US cities had detectable cockroach allergen.
Integrated Pest Management (IPM) is a multi-component approach to cockroach control that combines professional extermination using gel bait stations (avoiding chemical sprays that worsen asthma), sealing cracks and entry points, eliminating food and water access, mattress encasement, and ongoing hygiene. The ICAS (Inner-City Asthma Study, Morgan et al. NEJM 2004, 937 children across 7 US cities) documented that a tailored environmental intervention program including cockroach IPM as a key component produced 21.3 fewer symptom days per year (19.5% reduction), 2.1 fewer unscheduled medical visits, and 4.4 fewer missed school days compared to usual care. A NYC public housing study (Environ Health Perspect 2009) showed that a single professional IPM visit outperformed regular pesticide spray application. IPM is given Level A evidence in AAAAI/ACAAI Practice Parameters.
Yes — cockroach-sensitized patients have a clinically meaningful risk of reacting to shrimp, lobster, crab, and other shellfish through the tropomyosin cross-reactivity bridge. Bla g 7 (cockroach tropomyosin) shares approximately 80% amino acid identity with Pen a 1 (shrimp tropomyosin), creating genuine IgE cross-reactivity rather than just structural similarity. If you have confirmed cockroach allergy, a board-certified allergist should screen for shellfish reactions — particularly shrimp, which is the most commonly eaten shellfish in the US. This is different from the pollen-food allergy syndrome seen with tree pollens; it represents true cross-reactive IgE binding rather than protein family proximity.
Component-resolved testing for cockroach should include: Bla g 2 (the 36 kDa aspartic protease, ~57.6% reactivity, species-specific to German cockroach) which is the most clinically useful diagnostic marker; Bla g 5 (glutathione S-transferase, up to 70% reactivity in US cohorts); Bla g 1 (microvilli-like protein); and Bla g 7 (tropomyosin, relevant for cross-reactivity interpretation). For P. americana: Per a 2 (81% reactivity in Taiwan populations) and Per a 9 (arginine kinase). Testing both Bla g 1/2/5 and Bla g 7 helps differentiate genuine cockroach primary sensitization (Bla g 1/2/5 dominant) from tropomyosin-mediated cross-reactivity with dust mite (where Bla g 7 is the bridge allergen). This distinction matters because dust-mite SCIT (for which FDA-standardized extracts exist) may be more clinically appropriate than experimental cockroach SCIT.
The CRITICAL trial specifically enrolled children ages 8–17, making cockroach SCIT the most studied allergen immunotherapy in this pediatric age group — with a negative result. Given the CRITICAL trial findings, cockroach SCIT in children remains experimental and should be considered only for severe persistent cases where comprehensive IPM, optimized pharmacotherapy (ICS, LABA, leukotriene receptor antagonists), and addressing co-occurring dust-mite sensitization have all been implemented and found insufficient. The AAAAI/ACAAI Practice Parameter recommends IPM with Level A evidence as first-line. Any experimental cockroach SCIT in children requires explicit parental informed consent about the absence of demonstrated efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.